Investigators in Project 3 (M.K. Brenner, Leader) will seek to improve immunotherapy for neuroblastoma by genetically modifying Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (GTLs) to express receptors specific for GD2 and FRAME, two antigens expressed at high levels on most neuroblastoma cells, and for CCL2 (MCP-1), a neuroblastoma-secreted chemokine. This strategy is supported by clinical and laboratory studies in Years 1-4 of this grant, demonstrating consistently superior in vivo survival and functionality for EBV CTLs expressing GD2 via a chimeric antigen receptor (CAR) compared to GD2-CAR+ primary T cells not specific for EBV. To enhance the trafficking of GD2-CAR+ EBV CTLs to neuroblastoma deposits, Dr Brenner's group proposes to express CCR2, the receptor for CCL2, on their modified CTLs and confirm its activity and safety in a xenograft tumor model (Aim 1). Then, in a Phase 1 clinical trial, they will administer two aliquots of CAR+ EBV CTLs - one with and one without CCR2 expression - to lymphodepleted patients with relapsed neuroblastoma, immediately after autologous stem cell transplantation, to determine the safety, in vivo expansion and persistence of CCR2- vs. CCR2+ CTLs, the infiltration of each type of CTL into tumor sites and the effects on residual tumor (Aim 2). Finally, they will prepare PRAME-specific alpha-beta TCRs from the T cells of immune patients, express them in EBV CTLs, test the safety and efficacy of the modified cells in animal models of PRAME/EBV+ tumors, and determine whether infusion of a combination of GD2-CAR+ and PRAME-specific alpha-beta TCR+ CTLs produces additive or synergistic effects (Aim 3). This plan of research, if successful, will overcome two major obstacles to adoptive immunotherapy for neuroblastoma (limited expansion and trafficking of CTLs) and will stimulate numerous interactions with others in the program who are circumventing the immune evasion tactics of EBV-positive tumors (Projects 1 and 4) or modulating the tumor microenvironment to allow optimal T-cell function (Projects 2 and 4) Lay summary- The effectiveness of cancer immunotherapy is limited by many factors, including the inability of the immune cells to migrate to deposits of tumor cells and expand their numbers at the tumor site. This group will test several promising strategies that may by- pass these obstacles, leading to greater destruction of neuroblastoma cells by activated immune lymphocytes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA094237-10
Application #
8378615
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
10
Fiscal Year
2012
Total Cost
$267,201
Indirect Cost
$91,787
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Mohammed, Somala; Sukumaran, Sujita; Bajgain, Pradip et al. (2017) Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther 25:249-258
Heczey, Andras; Louis, Chrystal U; Savoldo, Barbara et al. (2017) CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther 25:2214-2224
Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2017) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol 176:688-704
Tanaka, Miyuki; Tashiro, Haruko; Omer, Bilal et al. (2017) Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res 23:3499-3509
Schmueck-Henneresse, Michael; Omer, Bilal; Shum, Thomas et al. (2017) Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol 199:348-362
Shum, Thomas; Omer, Bilal; Tashiro, Haruko et al. (2017) Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov 7:1238-1247
Tashiro, Haruko; Sauer, Tim; Shum, Thomas et al. (2017) Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther 25:2202-2213
Gomes-Silva, Diogo; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2017) Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep 21:17-26
Szoor, Arpad; Vaidya, Abishek; Velasquez, Mireya Paulina et al. (2017) T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Mol Ther Oncolytics 6:69-79
Yagyu, Shigeki; Hoyos, Valentina; Del Bufalo, Francesca et al. (2016) Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch. Mol Ther Methods Clin Dev 3:16003

Showing the most recent 10 out of 201 publications